Evommune, Inc.

XNYSHealth care

Last traded price · USD

$6.95

+15.07%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:41 IST · A quote does not mean the product is available to trade on your account.

Day's open: $6.65
Previous close: $6.04
Volume: 281,317
Day's high: $7.15
Day's low: $6.50

In brief

Evommune, Inc. is a health care company listed on the New York Stock Exchange, valued at about $252M.
Its shares closed at $6.04 on 4 Nov 2026, down 70.1% over the past year.
From India you can buy EVMN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Evommune, Inc. (EVMN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole EVMN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade EVMN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 3 months
1 month: −8.6% (SPY −1.6%, XLV +13.5%). 3 months: −53.6% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EVMN, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.04 was 27.4% below its 50-day average ($8.32) and 65.6% below its 200-day average ($17.57).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.4× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 352.2K shares was 0.4× the average of the 30 sessions before it (982.9K), as the price rose 1.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
3.5M shares sold short
3.5M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−8.6%

6 months−74.7%

Since Nov 6, 2025−70.1%

5 years—

Newswire

About

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Website

Notable moves

October 28, 2026
+22.29%
June 29, 2026
−40.23%
February 10, 2026
+70.87%

Evommune, Inc.

XNYSHealth care

Last traded price · USD

$6.95

+15.07%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:41 IST · A quote does not mean the product is available to trade on your account.

Day's open: $6.65
Previous close: $6.04
Volume: 281,317
Day's high: $7.15
Day's low: $6.50

In brief

Evommune, Inc. is a health care company listed on the New York Stock Exchange, valued at about $252M.
Its shares closed at $6.04 on 4 Nov 2026, down 70.1% over the past year.
From India you can buy EVMN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Evommune, Inc. (EVMN) shares from India?

Do I need the price of a whole EVMN share to invest?

How much can I invest in US stocks in a year?

Can I trade EVMN options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 3 months
1 month: −8.6% (SPY −1.6%, XLV +13.5%). 3 months: −53.6% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EVMN, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.04 was 27.4% below its 50-day average ($8.32) and 65.6% below its 200-day average ($17.57).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.4× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 352.2K shares was 0.4× the average of the 30 sessions before it (982.9K), as the price rose 1.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
3.5M shares sold short
3.5M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−8.6%

6 months−74.7%

Since Nov 6, 2025−70.1%

5 years—

Newswire

About

Website

Notable moves

October 28, 2026
+22.29%
June 29, 2026
−40.23%
February 10, 2026
+70.87%

Evommune, Inc.

Evommune, Inc. in brief

Behind SPY and its sector fund XLV over 3 months

Below its 50- and 200-day averages

Light volume: 0.4× its 30-session average on 4 Nov 2026

3.5M shares sold short

Evommune, Inc.

Evommune, Inc. in brief

Behind SPY and its sector fund XLV over 3 months

Below its 50- and 200-day averages

Light volume: 0.4× its 30-session average on 4 Nov 2026

3.5M shares sold short